In a Phase I/II study with ATIR™, safety and proof of concept were confirmed in terms of absence of grade III/IV GvHD, reduced rates of infection, reduced Transplant Related Mortality and high Overall Survival.
ATIR™ is currently in Phase II clinical development and has been granted Orphan Drug Designation both in the EU and the USA. In these regions, 20,000 to 25,000 patients a year are unable to find a suitable standard of care matched donor. Together, both regions represent a combined primary market potential of more than EUR 1 billion per year.
About Kiadis Pharma
Kiadis Pharma B.V. is a private, clinical stage biopharmaceutical company developing innovative and potentially life-saving therapies for patients with late stage blood cancers and related disorders who are in need of a transplant, an area of significant unmet medical need.Kiadis Pharma's lead product is ATIR™, a cell based product currently in Phase II development, which is designed to enable stem cell transplantations from partially mismatched (haploidentical) family donors. Kiadis Pharma is collaborating with internationally renowned centers in Europe and North America for the successful development and manufacturing of ATIR™. Kiadis Pharma is supported by a strong group of leading international investors including LSP, Alta Partners, DFJ Esprit, Quest for Growth, MedSciences Capital and NOM. Kiadis Pharma is based in Amsterdam, The Netherlands. Further information can be found at: http://www.kiadis.com Company Contact: Manfred Ruediger, CEO Kiadis Pharma Entrada 231-234 1096 EG AMSTERDAM The Netherlands Tel. +31-20-314-02-50 firstname.lastname@example.org Media and Investor Contact: Mary-Jane Elliott, Amber Bielecka M:Communications Tel: +44-(0)207-920-2333 email@example.com SOURCE Kiadis Pharma